2016 Archived Content
By holding the Re-Entering Antibacterial Discovery and Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to overcome the crisis of multidrug resistance, to revive the antibacterial pipeline, and to improve
antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange among all stakeholders participating in discovery and development of new antibacterial agents. It includes several
events listed below.
Ruben Tommasi, Ph.D.
Director, Global Policy, Merck
Eszter Nagy, M.D., Ph.D.
Co-Founder and CSO, Arsanis, Inc; Managing Director, Arsanis Biosciences GmbH
(Acting) Chief of Staff, Head, Special Projects & Portfolio Management, Biomedical Advanced Research and Development Authority (BARDA)
Todd A. Black, Ph.D.
Executive Director, Infectious Diseases Merck Research Laboratory
Chief Commercial Officer, Spero Therapeutics
Olga Lomovskaya, Ph.D.
Vice President, Biology, The Medicines Company
Executive Director, Antibacterial Innovation Alliance
Sean F. Brady, Ph.D.
Head, Laboratory of Genetically Encoded Small Molecules, The Rockefeller University
Kevin Outterson, J.D.
Visiting Fellow, Chatham House, Professor, Law, Health Law, Bioethics and Human Rights, Boston University School of Law